LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (8)
2014
-
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 12, pp. 1369-1378
2012
-
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179
2011
2010
-
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: Perspective of the Spanish National Health System
Journal of Clinical Pharmacy and Therapeutics, Vol. 35, Núm. 4, pp. 429-438
-
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition
Clinical Cancer Research, Vol. 16, Núm. 18, pp. 4654-4665
2009
-
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin
Journal of Thoracic Oncology, Vol. 4, Núm. 11, pp. 1397-1403
2008
-
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
Clinical and Translational Oncology, Vol. 10, Núm. 12, pp. 831-839
-
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer
Clinical Cancer Research, Vol. 14, Núm. 1, pp. 215-223